Octafluoropropane

Overview

Perflutren, a diagnostic drug that is intended to be used for contrast enhancement during the indicated echocardiographic procedures, is comprised of lipid-coated microspheres filled with octafluoropropane(OFP) gas. When exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultrasound machine. The difference in density between the gas-filled bubbles and the blood around them creates an increased level of contrast visible in the resulting ultrasound image. During echocardiography, activated Perflutren enhances images of the inner edges or borders of the heart, producing an improved image that may enable physicians to better diagnose patients.

Indication

Used as an ultrasound contrast imaging in cardiology and radiology.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Ultrasound with Subharmonic Imaging and Subharmonic Aided Pressure Estimation (SHAPE) to Identify Portal Hypertension	2025/01/28	NCT06797193	Not Applicable	Recruiting	Mayo Clinic
Contrast-enhanced Ultrasound in the Treatment of Acute Spinal Cord Injury	2024/10/23	NCT06654804	Phase 4	Recruiting	University of Washington
MRI-Guided Ultrasound Stimulated Microbubbles Radiation Treatment for Patients with Chest-Wall and Locally Advanced Breast Cancer	2024/10/09	NCT06633601	Phase 1	Recruiting	Sunnybrook Health Sciences Centre
SHAPE for ICP Assessment	2024/08/26	NCT06571786	Phase 2	Recruiting	Thomas Jefferson University
Novel Magnetic Resonance Imaging-Guided Ultrasound-Stimulated Microbubble Radiation Treatment for Patients With Chest-Wall and Locally Advanced Breast Cancer-Phase II	2023/12/29	NCT06185972	Phase 2	Not yet recruiting	Sunnybrook Health Sciences Centre
Contrast Enhanced Ultrasound Medical Imaging for Identifying Breast Masses	2023/12/14	NCT06171607	Phase 1	Recruiting	University of Southern California
Multiparametric Ultrasound for the Diagnosis of Clinically Significant Prostate Cancer	2023/09/06	NCT06024772	Phase 3	Not yet recruiting	Thomas Jefferson University
A Study of Renal Microvessel Imaging for Chronic Kidney Disease	2023/03/10	NCT05764642	Phase 2	ENROLLING_BY_INVITATION	Mayo Clinic
MRI-Guided Focused Ultrasound Radiosensitization for Patients With Malignant Melanoma and Non Melanoma Skin Cancer	2022/11/17	NCT05620290	Phase 1	Recruiting	Sunnybrook Health Sciences Centre
Contrast-Enhanced Ultrasound and Shear Wave Elastography for the Treatment of Lymphedema	2022/11/14	NCT05613946	Phase 1	Completed	Mayo Clinic

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
DEFINITY RT	Lantheus Medical Imaging, Inc.	11994-017	INTRAVENOUS	6.52 mg in 1 mL	3/13/2024
Definity	Lantheus Medical Imaging, Inc.	11994-011	INTRAVENOUS	6.52 mg in 1 mL	3/13/2024
Optison Perflutren Protein-Type A Microspheres	GE Healthcare Inc.	0407-2707	INTRAVENOUS	0.22 mg in 1 mL	8/25/2025

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
Luminity	Lantheus EU Limited,Atlantic Avenue,Westpark Business Campus,Shannon,Co. Clare,Ireland	Authorised	9/20/2006
Optison	GE Healthcare AS,Nycoveien 1,NO-0401 Oslo,Norway	Authorised	5/17/1998

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
OPTISON perflutren 660 microgram/3mL injection vial	75247	GE Healthcare Australia Pty Ltd	Medicine	A	11/15/2000
DEFINITY perflutren lipid microsphere injection vial	124808	Global Medical Solutions Australia Pty Limited T/A Radpharm Scientific	Medicine	A	1/30/2007

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
OPTISON SUSPENSION INYECTABLE	Ge Healthcare As	98065001	DISPERSIÓN INYECTABLE	Uso Hospitalario Y Centros De Diagnóstico Autorizados	Not Commercialized
OPTISON SUSPENSION INYECTABLE	Ge Healthcare As	98065002	DISPERSIÓN INYECTABLE	Uso Hospitalario Y Centros De Diagnóstico Autorizados	Commercialized
LUMINITY 150 MICROLITROS/ML GAS Y DISOLVENTE PARA SOLUCIÓN PARA DISPERSIÓN INYECTABLE Y PARA PERFUSIÓN	Lantheus Eu Limited	06361001	SOLUCIÓN INYECTABLE Y PARA PERFUSIÓN	Uso Hospitalario	Commercialized

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

Related News

FDA Expands Optison Ultrasound Enhancing Agent Approval for Pediatric Cardiac Imaging

4 months ago

The FDA has expanded approval for GE HealthCare's Optison, allowing the ultrasound enhancing agent to be used in pediatric patients with suboptimal echocardiograms, following successful Phase IV clinical trials.

Help Us Improve

Your feedback helps us provide better drug information and insights.

AI-Powered Research

Premium Access